![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance associated variants at baseline (part II)
|
|
|
Reported by Jules Levin
Intl Resistance Workshop, Sitges Spain June 5-9 2012
V Van Eygen1, K Thys1, J Vingerhoets1, C Van Hove2, LT Rimsky1, J Aerssens1 and GR Picchio3
1Janssen Infectious Diseases, Beerse, Belgium; 2Janssen Pharmaceutica, Beerse, Belgium; 3Janssen R&D Inc, Titusville, NJ, USA
![resistance1.gif](../images/062612/062612-2/resistance1.gif)
![resistance2.gif](../images/062612/062612-2/resistance2.gif)
![resistance3.gif](../images/062612/062612-2/resistance3.gif)
![resistance4.gif](../images/062612/062612-2/resistance4.gif)
![resistance5.gif](../images/062612/062612-2/resistance5.gif)
![resistance6.gif](../images/062612/062612-2/resistance6.gif)
![resistance7.gif](../images/062612/062612-2/resistance7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|